Progression of precision statin prescribing for reduction of statin-associated muscle symptoms.
Natasha J PetryJordan F BayeSamantha FrearKristen JacobsenAmanda MassmannApril SchultzJoel Van HeukelomKurt ChristensenPublished in: Pharmacogenomics (2022)
Background: Statins are among the most commonly prescribed medications, and improve patient outcomes by lowering cholesterol levels, but also have side effects. Variations in statin response can be attributed to a handful of factors that include pharmacogenetics. Methods: While not a true review article, this work was written using various search engines and terms and previous and newly published Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for statins to provide a historical perspective in addition to the current status of statin-related pharmacogenetics and future perspectives. Results: This article provides historical background on statins and associated adverse effects, reviews pharmacogenetic implications, applies clinical decision support, incorporates the latest CPIC guidelines and addresses future implications. Conclusion: Statins are a beneficial medication, but not without risk. Pharmacogenomics can help mitigate some risk factors. Clinical decision support, implementation, research and guidelines will continue to influence statin prescribing.
Keyphrases
- clinical decision support
- cardiovascular disease
- primary care
- low density lipoprotein
- electronic health record
- current status
- coronary artery disease
- healthcare
- risk factors
- adverse drug
- clinical practice
- type diabetes
- skeletal muscle
- quality improvement
- systematic review
- emergency department
- randomized controlled trial
- depressive symptoms
- sleep quality
- meta analyses